Quick read
Fair Value Engine
Decision-focused synthesis of expected stock prices combining relative peer multiples and intrinsic models.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Kroger Co
Latest stored price
The Cigna Group
Latest stored price
Decision snapshot
KR stock price vs CI: inconclusive
Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Price gap
N/A
Coverage
Medium · 60%
Free account · revisit it from your workspace
Quick read
Decision-focused synthesis of expected stock prices combining relative peer multiples and intrinsic models.
Metric-by-metric
Filter, sort, and scan where each company leads, where gaps are small, and where comparisons are not meaningful.
| Metric | KR | CI | Spread |
|---|---|---|---|
Revenue growth (YoY) KR: FY 2025 -> FY 2026 | CI: FY 2024 -> FY 2025 | 0.4% | 11.2% | CI leads by 96.9% Higher Revenue growth |
Gross margin | 51.6% | 21.8% | KR leads by 136.7% Higher Gross margin |
EBITDA margin | 2.0% | 4.0% | CI leads by 50.6% Higher EBITDA margin |
EV/Revenue | N/M | N/M | Insufficient data No additional context |
P/E | N/M | N/M | Not comparable Not comparable |
Net debt / EBITDA | 4.8 | 2.1 | CI leads by 130.7% Lower Net debt / EBITDA |
Statements
Core income statement and balance sheet metrics aligned to the reporting windows.
| Metric | KR | Delta vs CI | CI |
|---|---|---|---|
| Revenue | $147.64B | 46.3% lower | $274.90B |
| Gross profit | $76.15B | 27.1% higher | $59.91B |
| Operating income | $1.89B | 79.5% lower | $9.20B |
| EBITDA | $2.88B | 73.5% lower | $10.87B |
| Net income | $1.02B | 83.8% lower | $6.29B |
| EPS | 1.5 | 93.1% lower | 22.2 |
| Revenue growth | 0.4% | 96.9% lower | 11.2% |
| Gross margin | 51.6% | 136.7% higher | 21.8% |
| Operating margin | 1.3% | 61.7% lower | 3.3% |
| EBITDA margin | 2.0% | 50.6% lower | 4.0% |
| Net margin | 0.7% | 69.9% lower | 2.3% |
Trendline
Track multi-year revenue, earnings, and margin direction before underwriting a rerating.
Price framework
Market cap + debt - cash, shown for the current pair and benchmark median context.
Price framework
Baseline discounted cash flow model estimating total intrinsic firm value first, then bridging to an implied stock price per share.
Risk control
Financial health checks to separate durable balance sheets from potential value traps.
Comparable set
Place both companies in context relative to a wider comparable universe.
LLM-powered Synthesis
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
KR screens as expensive versus CI on earnings and cash-flow proxies despite a higher gross margin, while its weaker growth, lower profitability, and higher leverage do not justify the current relative valuation.
If you believe KR can materially improve revenue growth and margin conversion without worsening leverage, then consider holding or adding only on weakness, because the current 42.0x P/E is hard to justify versus CI's 13.4x given KR's 0.4% growth, 1.3% operating margin, and 4.8x net debt/EBITDA.
KR trades at 42.0x P/E versus CI at 13.4x, yet the implied price from the P/E comparison is $20.69, or 68.0% below KR's current price of $64.73. On asset/revenue multiples the picture is less extreme, with KR and CI both at 0.3x P/S and 0.4x EV/Revenue, suggesting the discount/premium debate is being driven mainly by earnings quality rather than top-line valuation.
Supporting Metrics